{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:52:41Z","timestamp":1771505561735,"version":"3.50.1"},"reference-count":29,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202106070028"],"award-info":[{"award-number":["202106070028"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,7,27]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine the long-term effectiveness of antihypertensive monotherapies in primary prevention of cardiovascular events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective inception cohort study covering a 25-year study period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>University Groningen IADB.nl pharmacy prescription database with data from 1996 to 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Patients aged 18 years or older, free of any cardiovascular disease (CVD) drug therapies prior to initiation of a preventive antihypertensive monotherapy (ACE inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), beta-blockers (BBs), calcium channel blockers (CCBs) and thiazides).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcome measures<\/jats:title>\n                  <jats:p>Primary outcome was the time to first prescription of acute cardiac drug therapy (CDT) measured by valid drug proxies to identify a first major CVD event in patients without a history of CVD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 33\u2009427 initiators, 5770 (17.3%) patients experienced an acute CDT. The average follow-up time was 7.8\u00b15.4 years. The 25-year incidence rate per 1000 person-years were 28.4, 25.2, 20.1, 28.4 and 25.2 for ACEI, ARB, BB, CCB and thiazide starters, respectively. Inverse probability weighted Cox regression showed that thiazide starters had lower hazards than the reference BB starters (HR: 0.88, 95%CI: 0.82 to 0.96). Among patients on diabetes drugs, risks were lower (HR: 0.58, 95%CI: 0.34 to 0.96). CCB starters had higher hazards than reference BB (HR: 1.26, 95% CI: 1.13 to 1.41). The overall estimated number needed to treat for thiazides compared with BBs to prevent one acute CDT in 25 years was 26, and five among patients on diabetes drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>After adjustments for confounders, patients starting on monotherapy with thiazides had a lower incidence of CDT compared with those starting on BBs, notably among patients on diabetes drugs. Conversely, patients who began CCB monotherapy had a higher incidence of CDT compared with those starting on BBs. Other monotherapies had comparable incidence of cardiovascular disease compared with BBs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-068721","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T13:21:09Z","timestamp":1691587269000},"page":"e068721","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term comparative effectiveness of antihypertensive monotherapies in primary prevention of cardiovascular events: a population-based retrospective inception cohort study in the Netherlands"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2175-8307","authenticated-orcid":false,"given":"Xuechun","family":"Li","sequence":"first","affiliation":[{"name":"PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J","family":"Bijlsma","sequence":"additional","affiliation":[{"name":"PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands"},{"name":"Laboratory of Population Health, Max-Planck-Institute for Demographic Research, Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens H J","family":"Bos","sequence":"additional","affiliation":[{"name":"PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catharina C M","family":"Schuiling-Veninga","sequence":"additional","affiliation":[{"name":"PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eelko","family":"Hak","sequence":"additional","affiliation":[{"name":"PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"2025101813102776000_13.8.e068721.1","unstructured":"WHO . Cardiovascular diseases (Cvds). n.d. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)"},{"key":"2025101813102776000_13.8.e068721.2","unstructured":"CBO . 1 out of 8 deaths in 2020 due to COVID-19. n.d. Available: https:\/\/www.cbs.nl\/en-gb\/news\/2021\/33\/1-out-of-8-deaths-in-2020-due-to-covid-19"},{"key":"2025101813102776000_13.8.e068721.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61299-9"},{"key":"2025101813102776000_13.8.e068721.4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1524-6175.2007.07177.x","article-title":"Evolving treatment options for prevention of cardiovascular events in high-risk hypertensive patients","volume":"9","author":"Deedwania","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025101813102776000_13.8.e068721.5","unstructured":"World Health Organization . Guideline for the pharmacological treatment of hypertension in adults. Geneva: World Health Organization, 2021."},{"key":"2025101813102776000_13.8.e068721.6","unstructured":"NH, en Innovatie K . Praktische Handleiding bij de NHG-Standaard CVRM 2019. Huisartsen Genootschap, Nederlands, 2019."},{"key":"2025101813102776000_13.8.e068721.7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"2025101813102776000_13.8.e068721.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32317-7"},{"key":"2025101813102776000_13.8.e068721.9","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-10-33","article-title":"Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis","volume":"10","author":"Fretheim","year":"2012","journal-title":"BMC Med"},{"key":"2025101813102776000_13.8.e068721.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2534"},{"key":"2025101813102776000_13.8.e068721.11","doi-asserted-by":"crossref","unstructured":"Cochrane Hypertension Group, Zhu J , Chen N , et al . Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev 2022;2022. doi:10.1002\/14651858.CD003654.pub6","DOI":"10.1002\/14651858.CD003654.pub6"},{"key":"2025101813102776000_13.8.e068721.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-017-0575-4","article-title":"Effectiveness and safety of beta blockers in the management of hypertension in older adults: a systematic review to help reduce inappropriate prescribing","volume":"17","author":"V\u00f6gele","year":"2017","journal-title":"BMC Geriatr"},{"key":"2025101813102776000_13.8.e068721.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective Epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"2025101813102776000_13.8.e068721.14","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.00213"},{"key":"2025101813102776000_13.8.e068721.15","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200206000-00038"},{"key":"2025101813102776000_13.8.e068721.16","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565040-00001"},{"key":"2025101813102776000_13.8.e068721.17","doi-asserted-by":"publisher","DOI":"10.1586\/erp.13.20"},{"key":"2025101813102776000_13.8.e068721.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214240","article-title":"Trends in Polypharmacy and dispensed drugs among adults in the Netherlands as compared to the United States","volume":"14","author":"Oktora","year":"2019","journal-title":"PLoS ONE"},{"key":"2025101813102776000_13.8.e068721.19","unstructured":"Methodology Wccfds. High-ceiling diuretics. n.d. Available: https:\/\/www.whocc.no\/atc_ddd_index\/?code=C03C"},{"key":"2025101813102776000_13.8.e068721.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-016-1361-2","article-title":"Identification of major cardiovascular events in patients with diabetes using primary care data","volume":"16","author":"Pouwels","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"2025101813102776000_13.8.e068721.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1940-x"},{"key":"2025101813102776000_13.8.e068721.22","unstructured":"Ridgeway G , McCaffrey DF , Morral AR , et al . Toolkit for weighting and analysis of nonequivalent groups: a tutorial for the R TWANG package. Santa Monica, CA: RAND Corporation, 2022. Available: https:\/\/www.rand.org\/pubs\/tools\/TLA570-5.html"},{"key":"2025101813102776000_13.8.e068721.23","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2018.01.36","article-title":"Estimate risk difference and number needed to treat in survival analysis","volume":"6","author":"Zhang","year":"2018","journal-title":"Ann Transl Med"},{"key":"2025101813102776000_13.8.e068721.24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ajh\/hpab137","article-title":"Prescription patterns for the use of antihypertensive drugs for primary prevention among patients with hypertension in the United Kingdom","volume":"35","author":"Jiao","year":"2022","journal-title":"Am J Hypertens"},{"key":"2025101813102776000_13.8.e068721.25","unstructured":"Genootschap NH . Cardiovascular risk management. n.d. Available: https:\/\/richtlijnen.nhg.org\/standaarden\/cardiovasculair-risicomanagement"},{"key":"2025101813102776000_13.8.e068721.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.23.2981"},{"key":"2025101813102776000_13.8.e068721.27","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet (London, England)"},{"key":"2025101813102776000_13.8.e068721.28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11883-022-00983-2","article-title":"Beta-blockers for Atherosclerosis prevention: a missed opportunity?","volume":"24","author":"Vrablik","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"2025101813102776000_13.8.e068721.29","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328310e0d9"}],"updated-by":[{"DOI":"10.1136\/bmjopen-2022-068721corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000}}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-068721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:10:36Z","timestamp":1760818236000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-068721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,9]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/bmjopen-2022-068721"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-068721","relation":{"correction":[{"id-type":"doi","id":"10.1136\/bmjopen-2022-068721corr1","asserted-by":"object"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}